875 related articles for article (PubMed ID: 22686415)
1. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
; Bosch J; Gerstein HC; Dagenais GR; Díaz R; Dyal L; Jung H; Maggiono AP; Probstfield J; Ramachandran A; Riddle MC; Rydén LE; Yusuf S
N Engl J Med; 2012 Jul; 367(4):309-18. PubMed ID: 22686415
[TBL] [Abstract][Full Text] [Related]
2. Basal insulin and cardiovascular and other outcomes in dysglycemia.
; Gerstein HC; Bosch J; Dagenais GR; Díaz R; Jung H; Maggioni AP; Pogue J; Probstfield J; Ramachandran A; Riddle MC; Rydén LE; Yusuf S
N Engl J Med; 2012 Jul; 367(4):319-28. PubMed ID: 22686416
[TBL] [Abstract][Full Text] [Related]
3. Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial.
Cukierman-Yaffe T; Bosch J; Diaz R; Dyal L; Hancu N; Hildebrandt P; Lanas F; Lewis BS; Marre M; Yale JF; Yusuf S; Gerstein HC;
Lancet Diabetes Endocrinol; 2014 Jul; 2(7):562-72. PubMed ID: 24898834
[TBL] [Abstract][Full Text] [Related]
4. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
[TBL] [Abstract][Full Text] [Related]
5. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
6. n-3 fatty acids and cardiovascular events after myocardial infarction.
Kromhout D; Giltay EJ; Geleijnse JM;
N Engl J Med; 2010 Nov; 363(21):2015-26. PubMed ID: 20929341
[TBL] [Abstract][Full Text] [Related]
7. n-3 fatty acids and cardiovascular outcomes in dysglycemia.
Hurtado-Torres GF; Sandoval-Munro RL
N Engl J Med; 2012 Nov; 367(18):1760-1; author reply 1761. PubMed ID: 23113492
[No Abstract] [Full Text] [Related]
8. n-3 fatty acids and cardiovascular outcomes in dysglycemia.
Levy Y
N Engl J Med; 2012 Nov; 367(18):1760; author reply 1761. PubMed ID: 23113491
[No Abstract] [Full Text] [Related]
9. ORIGIN trial shows safety and efficacy of insulin glargine: no adverse cardiovascular outcomes after a 6.2-year follow up of early insulin use.
Lombard L; Distiller L; Aalbers J
Cardiovasc J Afr; 2012 Jul; 23(6):357-8. PubMed ID: 23091824
[No Abstract] [Full Text] [Related]
10. Effect of nateglinide on the incidence of diabetes and cardiovascular events.
; Holman RR; Haffner SM; McMurray JJ; Bethel MA; Holzhauer B; Hua TA; Belenkov Y; Boolell M; Buse JB; Buckley BM; Chacra AR; Chiang FT; Charbonnel B; Chow CC; Davies MJ; Deedwania P; Diem P; Einhorn D; Fonseca V; Fulcher GR; Gaciong Z; Gaztambide S; Giles T; Horton E; Ilkova H; Jenssen T; Kahn SE; Krum H; Laakso M; Leiter LA; Levitt NS; Mareev V; Martinez F; Masson C; Mazzone T; Meaney E; Nesto R; Pan C; Prager R; Raptis SA; Rutten GE; Sandstroem H; Schaper F; Scheen A; Schmitz O; Sinay I; Soska V; Stender S; Tamás G; Tognoni G; Tuomilehto J; Villamil AS; Vozár J; Califf RM
N Engl J Med; 2010 Apr; 362(16):1463-76. PubMed ID: 20228402
[TBL] [Abstract][Full Text] [Related]
11. N-3 fatty acids did not reduce major cardiovascular events in patients with dysglycaemia.
Kromhout D
Evid Based Med; 2013 Aug; 18(4):e34. PubMed ID: 23173155
[No Abstract] [Full Text] [Related]
12. Effect of valsartan on the incidence of diabetes and cardiovascular events.
; McMurray JJ; Holman RR; Haffner SM; Bethel MA; Holzhauer B; Hua TA; Belenkov Y; Boolell M; Buse JB; Buckley BM; Chacra AR; Chiang FT; Charbonnel B; Chow CC; Davies MJ; Deedwania P; Diem P; Einhorn D; Fonseca V; Fulcher GR; Gaciong Z; Gaztambide S; Giles T; Horton E; Ilkova H; Jenssen T; Kahn SE; Krum H; Laakso M; Leiter LA; Levitt NS; Mareev V; Martinez F; Masson C; Mazzone T; Meaney E; Nesto R; Pan C; Prager R; Raptis SA; Rutten GE; Sandstroem H; Schaper F; Scheen A; Schmitz O; Sinay I; Soska V; Stender S; Tamás G; Tognoni G; Tuomilehto J; Villamil AS; Vozár J; Califf RM
N Engl J Med; 2010 Apr; 362(16):1477-90. PubMed ID: 20228403
[TBL] [Abstract][Full Text] [Related]
13. n-3 fatty acids in patients with multiple cardiovascular risk factors.
; Roncaglioni MC; Tombesi M; Avanzini F; Barlera S; Caimi V; Longoni P; Marzona I; Milani V; Silletta MG; Tognoni G; Marchioli R
N Engl J Med; 2013 May; 368(19):1800-8. PubMed ID: 23656645
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM;
N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628
[TBL] [Abstract][Full Text] [Related]
15. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H;
Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
[TBL] [Abstract][Full Text] [Related]
16. Effect of a multifactorial intervention on mortality in type 2 diabetes.
Gaede P; Lund-Andersen H; Parving HH; Pedersen O
N Engl J Med; 2008 Feb; 358(6):580-91. PubMed ID: 18256393
[TBL] [Abstract][Full Text] [Related]
17. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
18. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.
Schramm TK; Gislason GH; Køber L; Rasmussen S; Rasmussen JN; Abildstrøm SZ; Hansen ML; Folke F; Buch P; Madsen M; Vaag A; Torp-Pedersen C
Circulation; 2008 Apr; 117(15):1945-54. PubMed ID: 18378618
[TBL] [Abstract][Full Text] [Related]
19. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
Wilcox R; Kupfer S; Erdmann E;
Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
